生物源
mouse
品質等級
抗體表格
purified immunoglobulin
抗體產品種類
primary antibodies
無性繁殖
15B9.1, monoclonal
物種活性
rat, mouse, human
技術
immunohistochemistry: suitable
western blot: suitable
同型
IgG2aκ
NCBI登錄號
UniProt登錄號
運輸包裝
wet ice
目標翻譯後修改
unmodified
基因資訊
human ... CYP7A1(1581)
一般說明
细胞色素P450 7A1(CYP7A1、CYPVII),也称为胆固醇7-α-单加氧酶或胆固醇7-α-羟化酶,属于细胞色素P450家族,对胆固醇稳态很重要。CYP7A1通过在胆固醇的7位引入亲水部分来催化胆固醇分解代谢和胆汁酸生物合成中的限速步骤。CYP7A1主要在肝脏中检测到,可催化以下反应: 胆固醇+NADPH+O2=7-α-羟基胆固醇+NADP++H2O。CYP7A1被葡萄糖和胆甾胺上调,而被鹅去氧胆酸下调。
免疫原
对应于人Cyp7a1的带有GST标记的重组蛋白。
應用
免疫组织化学分析:一个代表性批次以1:50-1,000稀释度在大鼠和人肝组织中检测到Cyp7a1。
研究子类别
凋亡 - 附加
凋亡 - 附加
研究类别
细胞凋亡 & 癌症
细胞凋亡 & 癌症
该Cyp7a1抗体经验证可用于WB&IHC检测Cyp7a1蛋白。
品質
通过蛋白质印迹法在人肝组织裂解物中进行评价。
蛋白质印迹分析:0.5 µg/mL该抗体在10 µg人肝组织裂解物中检测到Cyp7a1。
蛋白质印迹分析:0.5 µg/mL该抗体在10 µg人肝组织裂解物中检测到Cyp7a1。
標靶描述
观测分子量〜52 kDa
外觀
形式:纯化
纯化的小鼠单克隆IgG2aκ,溶于含0.1 M Tris-甘氨酸(pH 7.4)、150 mM NaCl和0.05%叠氮化钠的缓冲液中。
纯化蛋白G
儲存和穩定性
自接收之日起,在2-8°C下可稳定保存1年。
分析報告
对照
人肝组织裂解物
人肝组织裂解物
其他說明
浓度:关于批次特定浓度请参见检验报告。
免責聲明
除非我们的目录或产品随附的其他公司文件中另有说明,否则我们的产品预期仅用于研究用途,不得用于任何其他目的,包括但不限于未经授权的商业用途、体外诊断用途、离体或体内治疗用途或对人类或动物的任何类型的消费或应用。
Not finding the right product?
Try our 产品选型工具.
儲存類別代碼
12 - Non Combustible Liquids
水污染物質分類(WGK)
WGK 1
閃點(°F)
Not applicable
閃點(°C)
Not applicable
Atorvastatin Modulates Bile Acid Homeostasis in Mice with Diet-Induced Nonalcoholic Steatohepatitis.
International journal of molecular sciences, 22(12) (2021-07-03)
Bile acids (BA) play a significant role in the pathophysiology of nonalcoholic steatohepatitis (NASH). The present study evaluates the modulation of bile acid metabolomics by atorvastatin, a cholesterol-lowering agent commonly used to treat cardiovascular complications accompanying NASH. NASH was induced
Cell death & disease, 8(10), e3110-e3110 (2017-10-13)
The p38α mitogen-activated protein kinase (MAPK) has been related to gluconeogenesis and lipid metabolism. However, the roles and related mechanisms of p38α MAPK in intestinal failure (IF)-associated liver steatosis remained poor understood. Here, our experimental evidence suggested that p38α MAPK
Acta pharmacologica Sinica, 40(7), 895-907 (2018-12-24)
The manipulation of bile acid (BA) homeostasis by blocking the ileal apical Na+-dependent bile salt transporter (ASBT/SLC10A2) may have therapeutic effects in nonalcoholic fatty liver disease. We developed a novel ASBT inhibitor, an N-(3,4-o-dichlorophenyl)-2-(3-trifluoromethoxy) benzamide derivative referred to as IMB17-15
Hepatology communications, 2(11), 1379-1391 (2018-11-10)
Bile acids (BAs) activate various dedicated receptors, including the farnesoid X receptor (FXR) and the Takeda G protein-coupled receptor 5 (TGR5). The FXR agonist obeticholic acid (OCA) is licensed for the treatment of primary biliary cholangitis and has shown promising
FEBS letters, 594(1), 114-125 (2019-08-23)
The immediate deterioration of primary human hepatocytes (PHHs) during culture limits their utility in drug discovery studies. Here, we report that a cocktail of four small molecule signaling inhibitors, termed YPAC, is useful for maintaining various hepatic functions of PHHs
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门